Join us for an insightful and forward-looking webinar that delves into how artificial intelligence (AI) and continuous glucose monitoring (CGM) are reshaping the future of personalized diabetes management.
Hear from renowned experts around the globe as they share the latest research, real-world applications, and clinical perspectives on how AI is being used to enhance diabetes management.
This webinar is supported by Dexcom.
Workshop Highlights
- Topic: AI & CGM: The New Era of Individualized Diabetes Management
- Date & Time: Tuesday, 1 July, at 12:00 CEST
- Duration: 1 Hour
- Speakers: Dr. Amit Kumar Dey, Dr. Elaine Chow, Dr. Inge Van Boxelaer and Dr. Nouran Yousef
Moderator
Assoc. Prof. Nouran Yousef
Assistant Professor of Pediatric Diabetes, Endocrinology, and Metabolism, Ain Shams University
Speakers
Dr. Amit Kumar Dey
Consultant Physician
Dr. Amit Kumar Dey is a Consultant Physician in Diabetology, Obesity, and Metabolic Disorders with over 12 years of experience. Based in Kolkata, India, he has received multiple accolades—including the Diabetes India 2020 Awareness Award, JPEF2023 Award, and the ACP India Chapter Governors Recognition Award (2024) for his work in AI in healthcare.
A certified member of the American Board of AI in Medicine (ABAIM), Dr. Dey is a Fellow of the Royal Society of Public Health (UK) and Diabetes India, and serves on the advisory board of the ACP India Chapter. He is the Founder Chair of Doctors AI, a 2,000+ member community exploring AI in medicine.
He also serves as Associate Editor of JMIR Diabetes, faculty at the National Diabetes Education Program (NDEP), and host of the global podcast “MedAI – Decoding AI in Healthcare.” His research focuses on AI in precision diabetes care, CGM in pregnancy, and diabetes in older adults.
Dr. Elaine Chow
Clinical Associate Professor, The Chinese University of Hong Kong
Dr. Elaine Chow is a physician-scientist trained in the UK with a PhD in cardiovascular effects of hypoglycemia in type 2 diabetes (University of Sheffield, 2015). Now based at the Chinese University of Hong Kong, she helped establish CGM and glucose clamp studies at the Phase 1 Clinical Trial Centre.
She leads multiple clinical studies in prediabetes, diabetes, and kidney disease and has been involved in over 100 Phase 1–4 trials on cardiometabolic therapies. Dr. Chow has earned numerous research grants and received awards such as the 2022 Richard Yu Lecture and ADA’s Women’s Interprofessional Network Abstract Award.
She also serves on advisory boards for Hong Kong’s Hospital Authority, is an associate editor for Diabetes Research and Clinical Practice, and sits on several journal editorial boards.
Dr. Inge Van Boxelaer
Endocrinologist, AZ St-Lucas Hospital in Ghent, Belgium
Dr. Inge Van Boxelaer is an endocrinologist and leading voice in diabetes technology, committed to advancing care for people with diabetes. Since 2013, she has practiced at AZ St-Lucas Hospital in Ghent and currently serves as President of the Belgian Society of Diabeto-Endocrinologists.
She is also involved with the Diabetes liga and Diabetesplus advisory boards and founded Diabetotech in 2020 to promote innovation in diabetes care. Through Diabetotech, she develops hands-on courses on insulin pumps and automated insulin delivery systems, all personally tested.
Clinician, educator, and entrepreneur—Dr. Van Boxelaer continues to drive progress in digital diabetes management across Belgium and beyond.
After the Webinar
After the webinar, you will be able to access the on-demand recording on the ATTD Educational Portal along with a CME/CPD accredited activity.
Dr. Salah has authored 36 international publications in highly indexed journals covering pediatric diabetes, obesity, and metabolism. She has also reviewed over 80 manuscripts on diabetes and obesity for leading international journals, including Cardiovascular Diabetology. Her main research interests include diabetes technology, obesity, insulin resistance, and diabetes management.
She is a member of the Early Career Education Committee of ATTD and was the recipient of the ATTD 2024 Award in recognition of her exceptional contributions to the field. Dr. Salah is committed to advancing global equity in access to diabetes technology and knowledge.